In November 2018, the US Food and Drug Administration (FDA) published 13 reports of stroke and cervicocephalic arterial dissection recorded over a 5-year period and attributed to alemtuzumab, an immunosup-pressant used in multiple sclerosis. Ten cases occurred in the US and three in Europe (1). Seven patients had a haemorrhagic stroke, one with dissection of both vertebral arteries. Two patients had an ischaemic stroke, including one case with dissection of both left and right carotid arteries and the right vertebral artery. Two patients had dissection of the right carotid artery and left vertebral artery, and two had an unspecified type of stroke. One of the patients who had a haemorrhagic stroke died.Twelve of the cases occurred within one day of receiving alemtuzumab and one case within three days (1).
展开▼
